PRESS RELEASE published on 05/10/2023 at 07:30, 3 years 1 month ago Formycon Announces Participation in International Investor Conferences in Q2/2023
PRESS RELEASE published on 04/27/2023 at 07:30, 3 years 2 months ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 3 years 2 months ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 3 years 4 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 3 years 4 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 4 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 3 years 4 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 3 years 4 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 4 months ago EQS-Adhoc: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 4 months ago EQS-Adhoc: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
Published on 06/27/2026 at 16:50, 23 hours 14 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 14 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 16 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 17 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 17 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 15 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 16 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 16 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
